News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thuris Corporation Names Kevin Lee To Drug Development And Clinical Board



10/19/2005 5:12:36 PM

IRVINE, Calif., Jan. 31 /PRNewswire/ -- Thuris Corporation, a privately held biopharmaceutical company focused on drug development for neurodegenerative diseases and neurological disorders, announced today that Dr. Kevin S. Lee has been appointed to the company's drug development and clinical board. Dr. Lee is the Harrison Foundation Professor and Chair of the Department of Neuroscience, and Professor of Neurological Surgery at the University of Virginia.

Gary Lynch, Ph.D., co-founder and Chief Scientist of Thuris said, "Kevin and I have worked together for many years, and he is as good as they come. I'm quite pleased to welcome him to the Thuris team, and I know that his input will be invaluable."

Kevin S. Lee, Ph.D., said, "It is a pleasure to be involved with the exciting drug development programs at Thuris. Diseases such as stroke exact a major toll on affected individuals, and society as a whole. The programs at Thuris hold great promise for the treatment of debilitating neurological disorders."

Keith B. Hoffman, Ph.D., Chief Operating Officer of Thuris, said, "Thuris is now poised to capitalize on significant scientific advances we've had in-house. Our next phase is to forward our pre-clinical leads into human clinical trials. The addition of Kevin Lee to our advisory board is a validation of our efforts to develop a drug for stroke-related neurological disorders. He is a recognized expert in the field and his involvement should accelerate our ability to get a drug candidate through human clinical trials."

About Thuris

Thuris is focused on pharmaceuticals to treat select Orphan and niche indications in-house, ranging from ischemia-related conditions, brain inflammation, and Huntington's disease. The future pursuit of Alzheimer's disease and Mild Cognitive Impairment will be in alliance with pharmaceutical partners.

Thuris is also the majority shareholder of Izalex, Inc. (R. Scott Greer, CEO), a company based upon the Thuris-invented NeuroGraph, a 510k-cleared, non-invasive medical device that will deliver much-needed objective patient data to the fields of psychiatry and neurology. [http://www.izalex.com]/

About Kevin Lee

Dr. Lee is the Harrison Foundation Professor and Chair of the Department of Neuroscience, and Professor of Neurological Surgery at the University of Virginia. Dr. Lee's laboratory is focused on ischemic pathology, neurovascular communication, and epilepsy. The lab utilizes multiple animal models of ischemic neuronal injury, single and multi-cell recordings, various anatomical/histological techniques, microsurgery, Gamma knife radiosurgery, and other related techniques. Kevin received his Ph.D. from the University of California in 1974, and worked for six years at the Max Planck Institute in Munich, Germany. He has served as a consultant to various pharmaceutical and biotechnology companies over the last 2 decades in the area of neurological disorders.

Thuris Corporation

CONTACT: Thuris Corporation, +1-949-417-4620


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES